Trizepatide

Trizepatide (tirzepatide) is described as a dual incretin receptor agonist that activates both GLP-1 and GIP receptors. The protocol explains that this dual mechanism increases glucose-dependent insulin secretion when glucose is present, suppresses glucagon output, slows gastric emptying, and promotes satiety through central appetite regulation. A key point emphasized is that the added GIP activity may amplify metabolic outcomes beyond GLP-1 agonism alone, which is presented as a reason trials have shown particularly strong weight-loss results. The page also highlights pharmacokinetics: an approximately 5-day half-life supports once-weekly administration with steady exposure. Mechanistically, the overall effect is improved glycemic control paired with reduced caloric intake and, over time, meaningful body-weight reduction—provided dosing is titrated gradually to improve tolerability.